PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-2.79%
Both yoy net incomes decline, with TRVN at -77.92%. Martin Whitman would view it as a broader sector or cyclical slump hitting profits.
-4.72%
Both reduce yoy D&A, with TRVN at -4.49%. Martin Whitman would suspect a lull in expansions or intangible additions for both.
No Data
No Data available this quarter, please select a different quarter.
-4.68%
Negative yoy SBC while TRVN is 15.53%. Joel Greenblatt would see less immediate dilution advantage if talent levels remain strong.
284.52%
Well above TRVN's 299.66% if positive yoy. Michael Burry would see a risk of bigger working capital demands vs. competitor, harming free cash flow.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
299.08%
AP growth of 299.08% while TRVN is zero at 0.00%. Bruce Berkowitz would see a moderate difference that might matter for short-term liquidity if expansions are large.
-348.88%
Negative yoy usage while TRVN is 497.44%. Joel Greenblatt would see a short-term advantage in freeing up capital unless competitor invests effectively in these lines.
208.62%
Some yoy increase while TRVN is negative at -11.11%. John Neff would see competitor possibly reining in intangible charges or revaluations more effectively than we do.
35.18%
Some CFO growth while TRVN is negative at -44.96%. John Neff would note a short-term liquidity lead over the competitor.
82.00%
Lower CapEx growth vs. TRVN's 190.52%, potentially boosting near-term free cash. David Dodd would confirm no missed expansions that competitor might exploit.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
82.00%
Lower net investing outflow yoy vs. TRVN's 372.01%, preserving short-term cash. David Dodd would confirm expansions remain sufficient.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.